Abstract
29 adolescents referred for excessive height prediction (HP) (9 boys with HP > 195 cm, 20 girls with HP > 180 cm) were treated for 9 to 15 months with bromocriptine (5 to 7.5 mg/day). Minor and transient side-effects were observed in 20% of the subjects at the beginning of the treatment. Treatment had to be stopped in one boy complaining of asthenia and headache. Puberty developed normally, 16 girls experienced menarche during treatment and one continued regular menses. Bromocriptine treatment induced: 1) a significant decrease (p< 0.001) in growth velocity from mean ± SEM 8.6 ± 0.6 to 5.2 ± 1.0 cm/year in boys and from 7.1 ± 0.3 to 4.6 ± 0.4 cm/year in girls; 2) a twofold mean increase in skeletal maturation rate. Adult height prediction was reduced significantly from 202 ± 1.6 cm to 195.4 ± 1.2 cm in boys, and from 184 ± 0.7 cm to 179.8 ± 0.8 cm in girls. These results confirm our previous report suggesting that bromocriptine is a valuable alternative to sex steroid treatment in order to limit the final height in excessively tall adolescents.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brion, D., Garcia, M. & Job, J. Bromocriptine treatment in tall adolescents: two years of clinical experience. Pediatr Res 18, 1227 (1984). https://doi.org/10.1203/00006450-198411000-00161
Issue Date:
DOI: https://doi.org/10.1203/00006450-198411000-00161